Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE — EMERALD  

Systemic Lupus Erythematosus Clinical Trial

Official title: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous

Status Recruiting

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.

Clinical Trial Description

Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as per their background disease. The cohorts are defined as follows: - Cohort 1: MAS in the context of sJIA and AOSD. - Cohort 2: MAS in the context of pediatric and adult SLE. The study has the objectives to investigate the efficacy, safety and tolerability, for 8 weeks, and PK and PD, QoL and immunogenicity in these 2 cohorts for up to 1 year after last dose of of emapalumab. Macrophage Activation Syndrome (MAS) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) systemic Juvenile Idiopathic Arthritis (sJIA) Adult-onset Still's Disease (AOSD) Systemic Lupus Erythematosus (SLE) ;

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Lymphohistiocytosis, Hemophagocytic
• Macrophage Activation Syndrome
• Systemic Lupus Erythematosus

• NCT number: NCT05001737
• Study type: Interventional
• Source: Swedish Orphan Biovitrum
• Contact: Adnan Mahmood, MD
• Phone: +46(0)8 697 20 00
• Email: Adnan.Mahmood@sobi.com
• Status: Recruiting
• Phase: Phase 3
• Start date: December 15, 2021
• Completion date: September 2025